Doctors test if skipping extra chemo based on Mid-Treatment biopsy is safe for AML patients
NCT ID NCT06323590
First seen May 11, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This study looks at what happens when doctors do not give a second round of chemotherapy right away based on the results of a standard mid-treatment bone marrow biopsy in adults with newly diagnosed acute myeloid leukemia (AML). About 60 participants will receive usual first chemotherapy, and researchers will track how many achieve complete remission. The goal is to learn whether the mid-biopsy results can safely guide treatment decisions without forcing extra chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.